Skip to main content

Corporate Profile

PrintBio is a privately held, clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products and living tissues and organs, engineered and produced on-demand for patients.  The Company was founded and is led by an experienced team of biotechnology founders and executives.

 

For questions regarding investment opportunities, email: investors@printbio.com

Learn More

Recent Updates

PrintBio Contributes 3D Bioprinting Expertise to ARPA-H PRINT Program for Kidney Bioprinting

| Press Releases | No Comments
PrintBio, a regenerative medicine and bioprinting company, today announced its participation in a major ARPA-H PRINT Program initiative aimed at addressing the nation’s growing organ shortage through the development of…

PrintBio Introduces DynaFlex™ Programmable Surgical Mesh (PSM) at American Hernia Society Meeting 2025

| Press Releases | No Comments
DynaFlex™ Incorporates MetaDirectional Flex™ Technology to Create the First-of-Its-Kind Programmable Mesh Our introduction of DynaFlex™ represents a new era in surgical repair. By giving surgeons programmable control over mesh mechanics,…

PrintBio Reorganizes and Expands Leadership Team with Key Commercial and Market Development Appointments

| Press Releases | No Comments
• Launches Hernia Division to Focus on Abdominal Wall Repair Solutions • Strengthens Leadership to Drive Market Readiness for Surgical Innovation These appointments, encompassing a remarkable depth of talent and…